Lilly commences plaque psoriasis treatment head to head trial

Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of ixekizumab when compared to guselkumab to treat adult patients with moderate-to-severe plaque psoriasis. Roughly 960 patients are expected to be included in the 24-week, multicentre, randomised, blinded, parallel-group trial. The trial’s primary objective is the

Continue Reading

Eli Lilly Reveal Positive Clinical Trial Results for Dulaglutide

Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide,  is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly

Continue Reading